All In MedTech

Device Trial Radar · NCT04882592

Noninvasive Spinal Neuromodulation Enables Locomotor Recovery in Individuals With Cerebral Palsy

Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

May 15, 2021

Primary completion

Dec 1, 2023

Study completion Dec 1, 2024

Sponsor

Lead sponsor
SpineX Inc.Not on our public-company list
Sponsor type
Industry
First posted
May 12, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 2 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Assessing the effects of noninvasive spinal cord neuromodulation on improving function in individuals with cerebral palsy

Conditions

  • Cerebral Palsy

Interventions

  • SCiPDevice

    Noninvasive spinal cord neuromodulator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stepping overground or on a treadmillTime frame: 3 months
  2. Gross Motor Functional Measure (GMFM)Time frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SpineX

    Los Angeles, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.